Lapatinib was approved by the US Food and Drug Administration (FDA) for the treatment of HER2+ breast cancer in combination with letrozole (Johnston et al., 2009) or capecitabine (Geyer et al., 2006) and shows promise when combined with trastuzumab (de Azambuja et al., 2014). Here, ERBB2 is linked to breast carcinoma.